The following table is a summary of corporate and other allocations for the three months ended March 31, 2023: | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2023 | | | | | Direct costs | | | $ | 41.2 | | | | | | Selling, general and administrative expenses | | | 55.1 | | | | | | Restructuring and other charges | | | 0.1 | | | | | | Foreign exchange gain (loss) | | | (1.0) | | | | | | Corporate and other allocations | | | $ | 95.4 | | | | | |
The components of the transfers to and from Labcorp during the three months ended March 31, 2023 were as follows: | | | | | | | | | | | | | | | Three Months Ended March 31, 2023 | | | | | | General financing activities | | | | $ | (63.4) | | Corporate allocations | | | | 87.9 | | Stock compensation expense | | | | 6.7 | | Total net transfers (to) from Former Parent | | | | $ | 31.2 | |
|